Hmabs (DrugBank: -)
1 disease| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 113 | 筋ジストロフィー | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2011-000176-33-IT (EUCTR) | 14/02/2011 | 23/02/2011 | Cell Therapy Of Duchenne Muscular Dystrophy by intra-arterial delivery of HLA-identical allogeneic mesoangioblasts - ND | Cell Therapy Of Duchenne Muscular Dystrophy by intra-arterial delivery of HLA-identical allogeneic mesoangioblasts - ND | Duchenne Muscolar Dystrophy MedDRA version: 9.1;Level: PT;Classification code 10013801 | INN or Proposed INN: Tacrolimus Product Name: hMABs Other descriptive name: HLA-identical allogeneic mesoangioblasts Product Name: hMABs Other descriptive name: HLA-identical allogeneic mesoangioblasts Product Name: hMABs Other descriptive name: HLA-identical allogeneic mesoangioblasts | FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR | NULL | Authorised-recruitment may be ongoing or finished | Female: no Male: yes | Italy |